Global Mesenchymal Stem Cells (MSC) Market to Reach $9.5 Billion by 2030

ReportLinker

The global economy is at a critical crossroads with a number of interlocking challenges and crises running in parallel. The uncertainty around how Russia`s war on Ukraine will play out this year and the war`s role in creating global instability means that the trouble on the inflation front is not over yet.

New York, March 07, 2023 (GLOBE NEWSWIRE) -- Reportlinker.com announces the release of the report "Global Mesenchymal Stem Cells (MSC) Industry" - https://www.reportlinker.com/p05961465/?utm_source=GNW
Food and fuel inflation will remain a persistent economic problem. Higher retail inflation will impact consumer confidence and spending. As governments combat inflation by raising interest rates, new job creation will slowdown and impact economic activity and growth. Lower capital expenditure is in the offing as companies go slow on investments, held back by inflation worries and weaker demand. With slower growth and high inflation, developed markets seem primed to enter into a recession. Fears of new COVID outbreaks and China’s already uncertain post-pandemic path poses a real risk of the world experiencing more acute supply chain pain and manufacturing disruptions this year. Volatile financial markets, growing trade tensions, stricter regulatory environment and pressure to mainstream climate change into economic decisions will compound the complexity of challenges faced. Year 2023 is expected to be tough year for most markets, investors and consumers. Nevertheless, there is always opportunity for businesses and their leaders who can chart a path forward with resilience and adaptability.

Global Mesenchymal Stem Cells (MSC) Market to Reach $9.5 Billion by 2030

In the changed post COVID-19 business landscape, the global market for Mesenchymal Stem Cells (MSC) estimated at US$3.8 Billion in the year 2022, is projected to reach a revised size of US$9.5 Billion by 2030, growing at aCAGR of 12.1% over the period 2022-2030. Bone Marrow, one of the segments analyzed in the report, is projected to record 13.5% CAGR and reach US$3.1 Billion by the end of the analysis period. Taking into account the ongoing post pandemic recovery, growth in the Adipose Tissues segment is readjusted to a revised 15.6% CAGR for the next 8-year period.

The U.S. Market is Estimated at $1.1 Billion, While China is Forecast to Grow at 11.4% CAGR

The Mesenchymal Stem Cells (MSC) market in the U.S. is estimated at US$1.1 Billion in the year 2022. China, the world`s second largest economy, is forecast to reach a projected market size of US$1.6 Billion by the year 2030 trailing a CAGR of 11.4% over the analysis period 2022 to 2030. Among the other noteworthy geographic markets are Japan and Canada, each forecast to grow at 10% and 9.7% respectively over the 2022-2030 period. Within Europe, Germany is forecast to grow at approximately 7.4% CAGR.

Select Competitors (Total 56 Featured)
- Cell Applications Inc.
- Celprogen Inc.
- Cyagen US Inc.
- Genlantis Inc.
- Lonza Group
- Mesoblast Limited
- MilliporeSigma
- Neuromics
- Orthofix International N.V.
- PromoCell GmbH
- R&D Systems Inc.
- ScienCell Research Laboratories
- Stemcell Technologies Inc.
- Stemedica Cell Technologies Inc.
- Thermo Fischer Scientific Inc.


Read the full report: https://www.reportlinker.com/p05961465/?utm_source=GNW

I. METHODOLOGY

II. EXECUTIVE SUMMARY

1. MARKET OVERVIEW
Influencer Market Insights
World Market Trajectories
Mesenchymal Stem Cells Market on a Rapid Growth Path
Recent Market Activity
Current and Future Analysis
The Present and Future of MSC Therapies
Select MSC-based Therapeutics
Mesenchymal Stem Cell Research
Completed Phase III Studies with MSCs
MSCs are Being Explored for Several New Treatment Possibilities
Widespread Commercialization of ’Off-the-Shelf’ MSCs to Become
a Reality
Software Companies Endeavour to Cash in on the Boom
Mesenchymal Stem Cells (MSC) - Global Key Competitors
Percentage Market Share in 2022 (E)
Competitive Market Presence - Strong/Active/Niche/Trivial for
Players Worldwide in 2022 (E)
Impact of Covid-19 and a Looming Global Recession

2. FOCUS ON SELECT PLAYERS
Cell Applications, Inc. (USA)
Celprogen, Inc. (USA)
Cyagen US Inc. (USA)
Genlantis, Inc. (USA)
Lonza Group (Switzerland)
Mesoblast Limited (Australia)
MilliporeSigma (USA)
Neuromics (USA)
Orthofix International N.V. (Italy)
PromoCell GmbH (Germany)
R&D Systems, Inc. (USA)
ScienCell Research Laboratories (USA)
Stemcell Technologies Inc. (Canada)
Stemedica Cell Technologies, Inc. (USA)
Thermo Fischer Scientific, Inc. (USA)
Vitro Biopharma (USA)

3. MARKET TRENDS & DRIVERS
Development of Regenerative Medicine Accelerates Demand for MSCs
Ageing Demographics to Drive Demand for Mesenchymal Stem Cell
Therapies
Global Aging Population Statistics - Opportunity Indicators
Growing Prevalence of Chronic Diseases Propels Demand for
Mesenchymal Stem Cells
Key Disease Statistics - Opportunity Indicators
Growing Volume of Orthopedic Procedures: An Opportunity for the
MSC Market
Adult Stem Cell Therapies on Growth Trajectory, as
Controversies Continue to Haunt Embryonic Stem Cell Research
Adult Stem Cells and Embryonic Stem Cells - A Comparison
MSCs Versus Embryonic or Induced Pluripotent Stem Cells
MSC Therapies - Immune to Ethical Issues Applicable to
Embryonic Stem Cells
MSCs - A Potential Vehicle for ’Targeted Drug Delivery’
Stem Cell Based Bone Grafts: Promising Growth Ahead
Loopholes Associated with In Vivo Properties Constrain
Therapeutic Advancements
Major Challenges Confronting Mesenchymal Stem Cell Market
Allogeneic MSCs - Offering Promise in Immunosuppressive and
Tissue Repair Therapy
Administration Route Determines the Effectiveness of MSCs

4. GLOBAL MARKET PERSPECTIVE
Table 1: World Recent Past, Current & Future Analysis for Other
Applications by Geographic Region - USA, Canada, Japan, China,
Europe, Asia-Pacific and Rest of World Markets - Independent
Analysis of Annual Sales in US$ Million for Years 2022 through
2030 and % CAGR

Table 2: World Historic Review for Other Applications by
Geographic Region - USA, Canada, Japan, China, Europe,
Asia-Pacific and Rest of World Markets - Independent Analysis
of Annual Sales in US$ Million for Years 2014 through 2021 and
% CAGR

Table 3: World 16-Year Perspective for Other Applications by
Geographic Region - Percentage Breakdown of Value Sales for
USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of
World for Years 2014, 2023 & 2030

Table 4: World Recent Past, Current & Future Analysis for
Mesenchymal Stem Cells (MSC) by Geographic Region - USA,
Canada, Japan, China, Europe, Asia-Pacific and Rest of World
Markets - Independent Analysis of Annual Sales in US$ Million
for Years 2022 through 2030 and % CAGR

Table 5: World Historic Review for Mesenchymal Stem Cells (MSC)
by Geographic Region - USA, Canada, Japan, China, Europe,
Asia-Pacific and Rest of World Markets - Independent Analysis
of Annual Sales in US$ Million for Years 2014 through 2021 and
% CAGR

Table 6: World 16-Year Perspective for Mesenchymal Stem Cells
(MSC) by Geographic Region - Percentage Breakdown of Value
Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and
Rest of World Markets for Years 2014, 2023 & 2030

Table 7: World Recent Past, Current & Future Analysis for Bone
Marrow by Geographic Region - USA, Canada, Japan, China,
Europe, Asia-Pacific and Rest of World Markets - Independent
Analysis of Annual Sales in US$ Million for Years 2022 through
2030 and % CAGR

Table 8: World Historic Review for Bone Marrow by Geographic
Region - USA, Canada, Japan, China, Europe, Asia-Pacific and
Rest of World Markets - Independent Analysis of Annual Sales in
US$ Million for Years 2014 through 2021 and % CAGR

Table 9: World 16-Year Perspective for Bone Marrow by
Geographic Region - Percentage Breakdown of Value Sales for
USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of
World for Years 2014, 2023 & 2030

Table 10: World Recent Past, Current & Future Analysis for
Adipose Tissues by Geographic Region - USA, Canada, Japan,
China, Europe, Asia-Pacific and Rest of World Markets -
Independent Analysis of Annual Sales in US$ Million for Years
2022 through 2030 and % CAGR

Table 11: World Historic Review for Adipose Tissues by
Geographic Region - USA, Canada, Japan, China, Europe,
Asia-Pacific and Rest of World Markets - Independent Analysis
of Annual Sales in US$ Million for Years 2014 through 2021 and
% CAGR

Table 12: World 16-Year Perspective for Adipose Tissues by
Geographic Region - Percentage Breakdown of Value Sales for
USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of
World for Years 2014, 2023 & 2030

Table 13: World Recent Past, Current & Future Analysis for
Fetal Liver by Geographic Region - USA, Canada, Japan, China,
Europe, Asia-Pacific and Rest of World Markets - Independent
Analysis of Annual Sales in US$ Million for Years 2022 through
2030 and % CAGR

Table 14: World Historic Review for Fetal Liver by Geographic
Region - USA, Canada, Japan, China, Europe, Asia-Pacific and
Rest of World Markets - Independent Analysis of Annual Sales in
US$ Million for Years 2014 through 2021 and % CAGR

Table 15: World 16-Year Perspective for Fetal Liver by
Geographic Region - Percentage Breakdown of Value Sales for
USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of
World for Years 2014, 2023 & 2030

Table 16: World Recent Past, Current & Future Analysis for Lung
by Geographic Region - USA, Canada, Japan, China, Europe,
Asia-Pacific and Rest of World Markets - Independent Analysis
of Annual Sales in US$ Million for Years 2022 through 2030 and
% CAGR

Table 17: World Historic Review for Lung by Geographic Region -
USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of
World Markets - Independent Analysis of Annual Sales in US$
Million for Years 2014 through 2021 and % CAGR

Table 18: World 16-Year Perspective for Lung by Geographic
Region - Percentage Breakdown of Value Sales for USA, Canada,
Japan, China, Europe, Asia-Pacific and Rest of World for Years
2014, 2023 & 2030

Table 19: World Recent Past, Current & Future Analysis for Cord
Blood by Geographic Region - USA, Canada, Japan, China, Europe,
Asia-Pacific and Rest of World Markets - Independent Analysis
of Annual Sales in US$ Million for Years 2022 through 2030 and
% CAGR

Table 20: World Historic Review for Cord Blood by Geographic
Region - USA, Canada, Japan, China, Europe, Asia-Pacific and
Rest of World Markets - Independent Analysis of Annual Sales in
US$ Million for Years 2014 through 2021 and % CAGR

Table 21: World 16-Year Perspective for Cord Blood by
Geographic Region - Percentage Breakdown of Value Sales for
USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of
World for Years 2014, 2023 & 2030

Table 22: World Recent Past, Current & Future Analysis for
Other Sources of MSC Isolation by Geographic Region - USA,
Canada, Japan, China, Europe, Asia-Pacific and Rest of World
Markets - Independent Analysis of Annual Sales in US$ Million
for Years 2022 through 2030 and % CAGR

Table 23: World Historic Review for Other Sources of MSC
Isolation by Geographic Region - USA, Canada, Japan, China,
Europe, Asia-Pacific and Rest of World Markets - Independent
Analysis of Annual Sales in US$ Million for Years 2014 through
2021 and % CAGR

Table 24: World 16-Year Perspective for Other Sources of MSC
Isolation by Geographic Region - Percentage Breakdown of Value
Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and
Rest of World for Years 2014, 2023 & 2030

Table 25: World Recent Past, Current & Future Analysis for
Disease Modelling by Geographic Region - USA, Canada, Japan,
China, Europe, Asia-Pacific and Rest of World Markets -
Independent Analysis of Annual Sales in US$ Million for Years
2022 through 2030 and % CAGR

Table 26: World Historic Review for Disease Modelling by
Geographic Region - USA, Canada, Japan, China, Europe,
Asia-Pacific and Rest of World Markets - Independent Analysis
of Annual Sales in US$ Million for Years 2014 through 2021 and
% CAGR

Table 27: World 16-Year Perspective for Disease Modelling by
Geographic Region - Percentage Breakdown of Value Sales for
USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of
World for Years 2014, 2023 & 2030

Table 28: World Recent Past, Current & Future Analysis for Drug
Development & Discovery by Geographic Region - USA, Canada,
Japan, China, Europe, Asia-Pacific and Rest of World Markets -
Independent Analysis of Annual Sales in US$ Million for Years
2022 through 2030 and % CAGR

Table 29: World Historic Review for Drug Development &
Discovery by Geographic Region - USA, Canada, Japan, China,
Europe, Asia-Pacific and Rest of World Markets - Independent
Analysis of Annual Sales in US$ Million for Years 2014 through
2021 and % CAGR

Table 30: World 16-Year Perspective for Drug Development &
Discovery by Geographic Region - Percentage Breakdown of Value
Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and
Rest of World for Years 2014, 2023 & 2030

Table 31: World Recent Past, Current & Future Analysis for Stem
Cell Banking by Geographic Region - USA, Canada, Japan, China,
Europe, Asia-Pacific and Rest of World Markets - Independent
Analysis of Annual Sales in US$ Million for Years 2022 through
2030 and % CAGR

Table 32: World Historic Review for Stem Cell Banking by
Geographic Region - USA, Canada, Japan, China, Europe,
Asia-Pacific and Rest of World Markets - Independent Analysis
of Annual Sales in US$ Million for Years 2014 through 2021 and
% CAGR

Table 33: World 16-Year Perspective for Stem Cell Banking by
Geographic Region - Percentage Breakdown of Value Sales for
USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of
World for Years 2014, 2023 & 2030

Table 34: World Recent Past, Current & Future Analysis for
Tissue Engineering by Geographic Region - USA, Canada, Japan,
China, Europe, Asia-Pacific and Rest of World Markets -
Independent Analysis of Annual Sales in US$ Million for Years
2022 through 2030 and % CAGR

Table 35: World Historic Review for Tissue Engineering by
Geographic Region - USA, Canada, Japan, China, Europe,
Asia-Pacific and Rest of World Markets - Independent Analysis
of Annual Sales in US$ Million for Years 2014 through 2021 and
% CAGR

Table 36: World 16-Year Perspective for Tissue Engineering by
Geographic Region - Percentage Breakdown of Value Sales for
USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of
World for Years 2014, 2023 & 2030

Table 37: World Recent Past, Current & Future Analysis for
Toxicology Studies by Geographic Region - USA, Canada, Japan,
China, Europe, Asia-Pacific and Rest of World Markets -
Independent Analysis of Annual Sales in US$ Million for Years
2022 through 2030 and % CAGR

Table 38: World Historic Review for Toxicology Studies by
Geographic Region - USA, Canada, Japan, China, Europe,
Asia-Pacific and Rest of World Markets - Independent Analysis
of Annual Sales in US$ Million for Years 2014 through 2021 and
% CAGR

Table 39: World 16-Year Perspective for Toxicology Studies by
Geographic Region - Percentage Breakdown of Value Sales for
USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of
World for Years 2014, 2023 & 2030

Table 40: World Mesenchymal Stem Cells (MSC) Market Analysis of
Annual Sales in US$ Million for Years 2014 through 2030

III. MARKET ANALYSIS

UNITED STATES
Mesenchymal Stem Cells (MSC) Market Presence - Strong/Active/
Niche/Trivial - Key Competitors in the United States for 2023
(E)
Table 41: USA Recent Past, Current & Future Analysis for
Mesenchymal Stem Cells (MSC) by Application - Disease
Modelling, Drug Development & Discovery, Stem Cell Banking,
Tissue Engineering, Toxicology Studies and Other Applications -
Independent Analysis of Annual Sales in US$ Million for the
Years 2022 through 2030 and % CAGR

Table 42: USA Historic Review for Mesenchymal Stem Cells (MSC)
by Application - Disease Modelling, Drug Development &
Discovery, Stem Cell Banking, Tissue Engineering, Toxicology
Studies and Other Applications Markets - Independent Analysis
of Annual Sales in US$ Million for Years 2014 through 2021 and
% CAGR

Table 43: USA 16-Year Perspective for Mesenchymal Stem Cells
(MSC) by Application - Percentage Breakdown of Value Sales for
Disease Modelling, Drug Development & Discovery, Stem Cell
Banking, Tissue Engineering, Toxicology Studies and Other
Applications for the Years 2014, 2023 & 2030

Table 44: USA Recent Past, Current & Future Analysis for
Mesenchymal Stem Cells (MSC) by Source of MSC Isolation - Bone
Marrow, Adipose Tissues, Fetal Liver, Lung, Cord Blood and
Other Sources of MSC Isolation - Independent Analysis of Annual
Sales in US$ Million for the Years 2022 through 2030 and % CAGR

Table 45: USA Historic Review for Mesenchymal Stem Cells (MSC)
by Source of MSC Isolation - Bone Marrow, Adipose Tissues,
Fetal Liver, Lung, Cord Blood and Other Sources of MSC
Isolation Markets - Independent Analysis of Annual Sales in US$
Million for Years 2014 through 2021 and % CAGR

Table 46: USA 16-Year Perspective for Mesenchymal Stem Cells
(MSC) by Source of MSC Isolation - Percentage Breakdown of
Value Sales for Bone Marrow, Adipose Tissues, Fetal Liver,
Lung, Cord Blood and Other Sources of MSC Isolation for the
Years 2014, 2023 & 2030

CANADA
Table 47: Canada Recent Past, Current & Future Analysis for
Mesenchymal Stem Cells (MSC) by Application - Disease
Modelling, Drug Development & Discovery, Stem Cell Banking,
Tissue Engineering, Toxicology Studies and Other Applications -
Independent Analysis of Annual Sales in US$ Million for the
Years 2022 through 2030 and % CAGR

Table 48: Canada Historic Review for Mesenchymal Stem Cells
(MSC) by Application - Disease Modelling, Drug Development &
Discovery, Stem Cell Banking, Tissue Engineering, Toxicology
Studies and Other Applications Markets - Independent Analysis
of Annual Sales in US$ Million for Years 2014 through 2021 and
% CAGR

Table 49: Canada 16-Year Perspective for Mesenchymal Stem Cells
(MSC) by Application - Percentage Breakdown of Value Sales for
Disease Modelling, Drug Development & Discovery, Stem Cell
Banking, Tissue Engineering, Toxicology Studies and Other
Applications for the Years 2014, 2023 & 2030

Table 50: Canada Recent Past, Current & Future Analysis for
Mesenchymal Stem Cells (MSC) by Source of MSC Isolation - Bone
Marrow, Adipose Tissues, Fetal Liver, Lung, Cord Blood and
Other Sources of MSC Isolation - Independent Analysis of Annual
Sales in US$ Million for the Years 2022 through 2030 and % CAGR

Table 51: Canada Historic Review for Mesenchymal Stem Cells
(MSC) by Source of MSC Isolation - Bone Marrow, Adipose
Tissues, Fetal Liver, Lung, Cord Blood and Other Sources of MSC
Isolation Markets - Independent Analysis of Annual Sales in US$
Million for Years 2014 through 2021 and % CAGR

Table 52: Canada 16-Year Perspective for Mesenchymal Stem Cells
(MSC) by Source of MSC Isolation - Percentage Breakdown of
Value Sales for Bone Marrow, Adipose Tissues, Fetal Liver,
Lung, Cord Blood and Other Sources of MSC Isolation for the
Years 2014, 2023 & 2030

JAPAN
Mesenchymal Stem Cells (MSC) Market Presence - Strong/Active/
Niche/Trivial - Key Competitors in Japan for 2023 (E)
Table 53: Japan Recent Past, Current & Future Analysis for
Mesenchymal Stem Cells (MSC) by Application - Disease
Modelling, Drug Development & Discovery, Stem Cell Banking,
Tissue Engineering, Toxicology Studies and Other Applications -
Independent Analysis of Annual Sales in US$ Million for the
Years 2022 through 2030 and % CAGR

Table 54: Japan Historic Review for Mesenchymal Stem Cells
(MSC) by Application - Disease Modelling, Drug Development &
Discovery, Stem Cell Banking, Tissue Engineering, Toxicology
Studies and Other Applications Markets - Independent Analysis
of Annual Sales in US$ Million for Years 2014 through 2021 and
% CAGR

Table 55: Japan 16-Year Perspective for Mesenchymal Stem Cells
(MSC) by Application - Percentage Breakdown of Value Sales for
Disease Modelling, Drug Development & Discovery, Stem Cell
Banking, Tissue Engineering, Toxicology Studies and Other
Applications for the Years 2014, 2023 & 2030

Table 56: Japan Recent Past, Current & Future Analysis for
Mesenchymal Stem Cells (MSC) by Source of MSC Isolation - Bone
Marrow, Adipose Tissues, Fetal Liver, Lung, Cord Blood and
Other Sources of MSC Isolation - Independent Analysis of Annual
Sales in US$ Million for the Years 2022 through 2030 and % CAGR

Table 57: Japan Historic Review for Mesenchymal Stem Cells
(MSC) by Source of MSC Isolation - Bone Marrow, Adipose
Tissues, Fetal Liver, Lung, Cord Blood and Other Sources of MSC
Isolation Markets - Independent Analysis of Annual Sales in US$
Million for Years 2014 through 2021 and % CAGR

Table 58: Japan 16-Year Perspective for Mesenchymal Stem Cells
(MSC) by Source of MSC Isolation - Percentage Breakdown of
Value Sales for Bone Marrow, Adipose Tissues, Fetal Liver,
Lung, Cord Blood and Other Sources of MSC Isolation for the
Years 2014, 2023 & 2030

CHINA
Mesenchymal Stem Cells (MSC) Market Presence - Strong/Active/
Niche/Trivial - Key Competitors in China for 2023 (E)
Table 59: China Recent Past, Current & Future Analysis for
Mesenchymal Stem Cells (MSC) by Application - Disease
Modelling, Drug Development & Discovery, Stem Cell Banking,
Tissue Engineering, Toxicology Studies and Other Applications -
Independent Analysis of Annual Sales in US$ Million for the
Years 2022 through 2030 and % CAGR

Table 60: China Historic Review for Mesenchymal Stem Cells
(MSC) by Application - Disease Modelling, Drug Development &
Discovery, Stem Cell Banking, Tissue Engineering, Toxicology
Studies and Other Applications Markets - Independent Analysis
of Annual Sales in US$ Million for Years 2014 through 2021 and
% CAGR

Table 61: China 16-Year Perspective for Mesenchymal Stem Cells
(MSC) by Application - Percentage Breakdown of Value Sales for
Disease Modelling, Drug Development & Discovery, Stem Cell
Banking, Tissue Engineering, Toxicology Studies and Other
Applications for the Years 2014, 2023 & 2030

Table 62: China Recent Past, Current & Future Analysis for
Mesenchymal Stem Cells (MSC) by Source of MSC Isolation - Bone
Marrow, Adipose Tissues, Fetal Liver, Lung, Cord Blood and
Other Sources of MSC Isolation - Independent Analysis of Annual
Sales in US$ Million for the Years 2022 through 2030 and % CAGR

Table 63: China Historic Review for Mesenchymal Stem Cells
(MSC) by Source of MSC Isolation - Bone Marrow, Adipose
Tissues, Fetal Liver, Lung, Cord Blood and Other Sources of MSC
Isolation Markets - Independent Analysis of Annual Sales in US$
Million for Years 2014 through 2021 and % CAGR

Table 64: China 16-Year Perspective for Mesenchymal Stem Cells
(MSC) by Source of MSC Isolation - Percentage Breakdown of
Value Sales for Bone Marrow, Adipose Tissues, Fetal Liver,
Lung, Cord Blood and Other Sources of MSC Isolation for the
Years 2014, 2023 & 2030

EUROPE
Mesenchymal Stem Cells (MSC) Market Presence - Strong/Active/
Niche/Trivial - Key Competitors in Europe for 2023 (E)
Table 65: Europe Recent Past, Current & Future Analysis for
Mesenchymal Stem Cells (MSC) by Application - Disease
Modelling, Drug Development & Discovery, Stem Cell Banking,
Tissue Engineering, Toxicology Studies and Other Applications -
Independent Analysis of Annual Sales in US$ Million for the
Years 2022 through 2030 and % CAGR

Table 66: Europe Historic Review for Mesenchymal Stem Cells
(MSC) by Application - Disease Modelling, Drug Development &
Discovery, Stem Cell Banking, Tissue Engineering, Toxicology
Studies and Other Applications Markets - Independent Analysis
of Annual Sales in US$ Million for Years 2014 through 2021 and
% CAGR

Table 67: Europe 16-Year Perspective for Mesenchymal Stem Cells
(MSC) by Application - Percentage Breakdown of Value Sales for
Disease Modelling, Drug Development & Discovery, Stem Cell
Banking, Tissue Engineering, Toxicology Studies and Other
Applications for the Years 2014, 2023 & 2030

Table 68: Europe Recent Past, Current & Future Analysis for
Mesenchymal Stem Cells (MSC) by Geographic Region - France,
Germany, Italy, UK and Rest of Europe Markets - Independent
Analysis of Annual Sales in US$ Million for Years 2022 through
2030 and % CAGR

Table 69: Europe Historic Review for Mesenchymal Stem Cells
(MSC) by Geographic Region - France, Germany, Italy, UK and
Rest of Europe Markets - Independent Analysis of Annual Sales
in US$ Million for Years 2014 through 2021 and % CAGR

Table 70: Europe 16-Year Perspective for Mesenchymal Stem Cells
(MSC) by Geographic Region - Percentage Breakdown of Value
Sales for France, Germany, Italy, UK and Rest of Europe Markets
for Years 2014, 2023 & 2030

Table 71: Europe Recent Past, Current & Future Analysis for
Mesenchymal Stem Cells (MSC) by Source of MSC Isolation - Bone
Marrow, Adipose Tissues, Fetal Liver, Lung, Cord Blood and
Other Sources of MSC Isolation - Independent Analysis of Annual
Sales in US$ Million for the Years 2022 through 2030 and % CAGR

Table 72: Europe Historic Review for Mesenchymal Stem Cells
(MSC) by Source of MSC Isolation - Bone Marrow, Adipose
Tissues, Fetal Liver, Lung, Cord Blood and Other Sources of MSC
Isolation Markets - Independent Analysis of Annual Sales in US$
Million for Years 2014 through 2021 and % CAGR

Table 73: Europe 16-Year Perspective for Mesenchymal Stem Cells
(MSC) by Source of MSC Isolation - Percentage Breakdown of
Value Sales for Bone Marrow, Adipose Tissues, Fetal Liver,
Lung, Cord Blood and Other Sources of MSC Isolation for the
Years 2014, 2023 & 2030

FRANCE
Mesenchymal Stem Cells (MSC) Market Presence - Strong/Active/
Niche/Trivial - Key Competitors in France for 2023 (E)
Table 74: France Recent Past, Current & Future Analysis for
Mesenchymal Stem Cells (MSC) by Application - Disease
Modelling, Drug Development & Discovery, Stem Cell Banking,
Tissue Engineering, Toxicology Studies and Other Applications -
Independent Analysis of Annual Sales in US$ Million for the
Years 2022 through 2030 and % CAGR

Table 75: France Historic Review for Mesenchymal Stem Cells
(MSC) by Application - Disease Modelling, Drug Development &
Discovery, Stem Cell Banking, Tissue Engineering, Toxicology
Studies and Other Applications Markets - Independent Analysis
of Annual Sales in US$ Million for Years 2014 through 2021 and
% CAGR

Table 76: France 16-Year Perspective for Mesenchymal Stem Cells
(MSC) by Application - Percentage Breakdown of Value Sales for
Disease Modelling, Drug Development & Discovery, Stem Cell
Banking, Tissue Engineering, Toxicology Studies and Other
Applications for the Years 2014, 2023 & 2030

Table 77: France Recent Past, Current & Future Analysis for
Mesenchymal Stem Cells (MSC) by Source of MSC Isolation - Bone
Marrow, Adipose Tissues, Fetal Liver, Lung, Cord Blood and
Other Sources of MSC Isolation - Independent Analysis of Annual
Sales in US$ Million for the Years 2022 through 2030 and % CAGR

Table 78: France Historic Review for Mesenchymal Stem Cells
(MSC) by Source of MSC Isolation - Bone Marrow, Adipose
Tissues, Fetal Liver, Lung, Cord Blood and Other Sources of MSC
Isolation Markets - Independent Analysis of Annual Sales in US$
Million for Years 2014 through 2021 and % CAGR

Table 79: France 16-Year Perspective for Mesenchymal Stem Cells
(MSC) by Source of MSC Isolation - Percentage Breakdown of
Value Sales for Bone Marrow, Adipose Tissues, Fetal Liver,
Lung, Cord Blood and Other Sources of MSC Isolation for the
Years 2014, 2023 & 2030

GERMANY
Mesenchymal Stem Cells (MSC) Market Presence - Strong/Active/
Niche/Trivial - Key Competitors in Germany for 2023 (E)
Table 80: Germany Recent Past, Current & Future Analysis for
Mesenchymal Stem Cells (MSC) by Application - Disease
Modelling, Drug Development & Discovery, Stem Cell Banking,
Tissue Engineering, Toxicology Studies and Other Applications -
Independent Analysis of Annual Sales in US$ Million for the
Years 2022 through 2030 and % CAGR

Table 81: Germany Historic Review for Mesenchymal Stem Cells
(MSC) by Application - Disease Modelling, Drug Development &
Discovery, Stem Cell Banking, Tissue Engineering, Toxicology
Studies and Other Applications Markets - Independent Analysis
of Annual Sales in US$ Million for Years 2014 through 2021 and
% CAGR

Table 82: Germany 16-Year Perspective for Mesenchymal Stem
Cells (MSC) by Application - Percentage Breakdown of Value
Sales for Disease Modelling, Drug Development & Discovery, Stem
Cell Banking, Tissue Engineering, Toxicology Studies and Other
Applications for the Years 2014, 2023 & 2030

Table 83: Germany Recent Past, Current & Future Analysis for
Mesenchymal Stem Cells (MSC) by Source of MSC Isolation - Bone
Marrow, Adipose Tissues, Fetal Liver, Lung, Cord Blood and
Other Sources of MSC Isolation - Independent Analysis of Annual
Sales in US$ Million for the Years 2022 through 2030 and % CAGR

Table 84: Germany Historic Review for Mesenchymal Stem Cells
(MSC) by Source of MSC Isolation - Bone Marrow, Adipose
Tissues, Fetal Liver, Lung, Cord Blood and Other Sources of MSC
Isolation Markets - Independent Analysis of Annual Sales in US$
Million for Years 2014 through 2021 and % CAGR

Table 85: Germany 16-Year Perspective for Mesenchymal Stem
Cells (MSC) by Source of MSC Isolation - Percentage Breakdown
of Value Sales for Bone Marrow, Adipose Tissues, Fetal Liver,
Lung, Cord Blood and Other Sources of MSC Isolation for the
Years 2014, 2023 & 2030

ITALY
Table 86: Italy Recent Past, Current & Future Analysis for
Mesenchymal Stem Cells (MSC) by Application - Disease
Modelling, Drug Development & Discovery, Stem Cell Banking,
Tissue Engineering, Toxicology Studies and Other Applications -
Independent Analysis of Annual Sales in US$ Million for the
Years 2022 through 2030 and % CAGR

Table 87: Italy Historic Review for Mesenchymal Stem Cells
(MSC) by Application - Disease Modelling, Drug Development &
Discovery, Stem Cell Banking, Tissue Engineering, Toxicology
Studies and Other Applications Markets - Independent Analysis
of Annual Sales in US$ Million for Years 2014 through 2021 and
% CAGR

Table 88: Italy 16-Year Perspective for Mesenchymal Stem Cells
(MSC) by Application - Percentage Breakdown of Value Sales for
Disease Modelling, Drug Development & Discovery, Stem Cell
Banking, Tissue Engineering, Toxicology Studies and Other
Applications for the Years 2014, 2023 & 2030

Table 89: Italy Recent Past, Current & Future Analysis for
Mesenchymal Stem Cells (MSC) by Source of MSC Isolation - Bone
Marrow, Adipose Tissues, Fetal Liver, Lung, Cord Blood and
Other Sources of MSC Isolation - Independent Analysis of Annual
Sales in US$ Million for the Years 2022 through 2030 and % CAGR

Table 90: Italy Historic Review for Mesenchymal Stem Cells
(MSC) by Source of MSC Isolation - Bone Marrow, Adipose
Tissues, Fetal Liver, Lung, Cord Blood and Other Sources of MSC
Isolation Markets - Independent Analysis of Annual Sales in US$
Million for Years 2014 through 2021 and % CAGR

Table 91: Italy 16-Year Perspective for Mesenchymal Stem Cells
(MSC) by Source of MSC Isolation - Percentage Breakdown of
Value Sales for Bone Marrow, Adipose Tissues, Fetal Liver,
Lung, Cord Blood and Other Sources of MSC Isolation for the
Years 2014, 2023 & 2030

UNITED KINGDOM
Mesenchymal Stem Cells (MSC) Market Presence - Strong/Active/
Niche/Trivial - Key Competitors in the United Kingdom for 2023
(E)
Table 92: UK Recent Past, Current & Future Analysis for
Mesenchymal Stem Cells (MSC) by Application - Disease
Modelling, Drug Development & Discovery, Stem Cell Banking,
Tissue Engineering, Toxicology Studies and Other Applications -
Independent Analysis of Annual Sales in US$ Million for the
Years 2022 through 2030 and % CAGR

Table 93: UK Historic Review for Mesenchymal Stem Cells (MSC)
by Application - Disease Modelling, Drug Development &
Discovery, Stem Cell Banking, Tissue Engineering, Toxicology
Studies and Other Applications Markets - Independent Analysis
of Annual Sales in US$ Million for Years 2014 through 2021 and
% CAGR

Table 94: UK 16-Year Perspective for Mesenchymal Stem Cells
(MSC) by Application - Percentage Breakdown of Value Sales for
Disease Modelling, Drug Development & Discovery, Stem Cell
Banking, Tissue Engineering, Toxicology Studies and Other
Applications for the Years 2014, 2023 & 2030

Table 95: UK Recent Past, Current & Future Analysis for
Mesenchymal Stem Cells (MSC) by Source of MSC Isolation - Bone
Marrow, Adipose Tissues, Fetal Liver, Lung, Cord Blood and
Other Sources of MSC Isolation - Independent Analysis of Annual
Sales in US$ Million for the Years 2022 through 2030 and % CAGR

Table 96: UK Historic Review for Mesenchymal Stem Cells (MSC)
by Source of MSC Isolation - Bone Marrow, Adipose Tissues,
Fetal Liver, Lung, Cord Blood and Other Sources of MSC
Isolation Markets - Independent Analysis of Annual Sales in US$
Million for Years 2014 through 2021 and % CAGR

Table 97: UK 16-Year Perspective for Mesenchymal Stem Cells
(MSC) by Source of MSC Isolation - Percentage Breakdown of
Value Sales for Bone Marrow, Adipose Tissues, Fetal Liver,
Lung, Cord Blood and Other Sources of MSC Isolation for the
Years 2014, 2023 & 2030

REST OF EUROPE
Table 98: Rest of Europe Recent Past, Current & Future Analysis
for Mesenchymal Stem Cells (MSC) by Application - Disease
Modelling, Drug Development & Discovery, Stem Cell Banking,
Tissue Engineering, Toxicology Studies and Other Applications -
Independent Analysis of Annual Sales in US$ Million for the
Years 2022 through 2030 and % CAGR

Table 99: Rest of Europe Historic Review for Mesenchymal Stem
Cells (MSC) by Application - Disease Modelling, Drug
Development & Discovery, Stem Cell Banking, Tissue Engineering,
Toxicology Studies and Other Applications Markets - Independent
Analysis of Annual Sales in US$ Million for Years 2014 through
2021 and % CAGR

Table 100: Rest of Europe 16-Year Perspective for Mesenchymal
Stem Cells (MSC) by Application - Percentage Breakdown of Value
Sales for Disease Modelling, Drug Development & Discovery, Stem
Cell Banking, Tissue Engineering, Toxicology Studies and Other
Applications for the Years 2014, 2023 & 2030

Table 101: Rest of Europe Recent Past, Current & Future
Analysis for Mesenchymal Stem Cells (MSC) by Source of MSC
Isolation - Bone Marrow, Adipose Tissues, Fetal Liver, Lung,
Cord Blood and Other Sources of MSC Isolation - Independent
Analysis of Annual Sales in US$ Million for the Years 2022
through 2030 and % CAGR

Table 102: Rest of Europe Historic Review for Mesenchymal Stem
Cells (MSC) by Source of MSC Isolation - Bone Marrow, Adipose
Tissues, Fetal Liver, Lung, Cord Blood and Other Sources of MSC
Isolation Markets - Independent Analysis of Annual Sales in US$
Million for Years 2014 through 2021 and % CAGR

Table 103: Rest of Europe 16-Year Perspective for Mesenchymal
Stem Cells (MSC) by Source of MSC Isolation - Percentage

Please contact our Customer Support Center to get the complete Table of Contents
Read the full report: https://www.reportlinker.com/p05961465/?utm_source=GNW

About Reportlinker
ReportLinker is an award-winning market research solution. Reportlinker finds and organizes the latest industry data so you get all the market research you need - instantly, in one place.

__________________________

CONTACT: Clare: clare@reportlinker.com US: (339)-368-6001 Intl: +1 339-368-6001